All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, August 10, 2022
Home » Topics » Financings, BioWorld Asia

Financings, BioWorld Asia
Financings, BioWorld Asia RSS Feed RSS

HKEX building

Keymed raises $378M in Hong Kong debut

July 13, 2021
By Gina Lee
No Comments
Keymed Biosciences Inc. debuted on the Hong Kong Stock Exchange (HKSE) on July 8, raising HK$2.94 billion (US$378.48 million) in the process. The company will use the funds raised for the R&D and commercialization of key pipeline candidates.
Read More

Amaroq Therapeutics launches with NZ$14M seed funding to develop long non-coding RNA therapies

July 13, 2021
By Tamra Sami
No Comments
PERTH, Australia – Amaroq Therapeutics Ltd., a spinout out of the University of Otago in Dunedin, New Zealand, has launched after securing NZ$14 million (US$9.7 million) in seed funding to develop long non-coding RNAs to treat breast, colorectal and liver cancer.
Read More
Hong Kong stock market illustration

Brii Biosciences debuts in Hong Kong with $319M IPO, shares close 3.15% higher

July 13, 2021
By Doris Yu
No Comments
Brii Biosciences Ltd. raised HK$2.482 billion (US$319 million) in its IPO in Hong Kong and will use the proceeds to support the development of its key assets, which includes programs for hepatitis B virus (HBV), HIV and drug-resistant infections.
Read More
Q-biotics-Fontainea-flower 7-13
Newco news

Qbiotics closes AU$85M capital raise to progress plant-derived oncology, wound healing assets

July 13, 2021
By Tamra Sami
No Comments

PERTH, Australia – Following a AU$85 million (US$64.41 million) capital raise, Qbiotics Group Ltd. is progressing its oncology clinical program for lead candidate tigilanol tiglate, a natural product that is isolated from the seed of the Australian rainforest native shrub Fontainea.


Read More

Financings for July 13, 2021

July 13, 2021
No Comments
Biopharmas in Asia-Pacific raising money in public or private financings, including: Eisbach, Hutchmed.
Read More

Hutchmed debuts in Hong Kong with $537M IPO, shares jump 53%

July 6, 2021
By Elise Mak and Angie Ling
No Comments
Hutchmed Ltd., already listed in the U.S. and London, returned to home soil June 30 for a third IPO on the Hong Kong Stock Exchange that reaped HK$4.17 billion (US$537.2 million). The Hong Kong-based company is currently looking to score its first FDA approval to tap the U.S. market after three China approvals.
Read More
Shanghai, China, stock market illustration

With nod for Shanghai listing, Beigene to have shares in U.S., Hong Kong and mainland China

July 6, 2021
By Alfred Romann
No Comments
Beigene Ltd. got the green light for an IPO on the Shanghai Stock Exchange’s Science and Technology Innovation Board, a specialized board known as the STAR Market, that could be worth around $3 billion. It would make Beigene the first biotech company with listings in the U.S., Hong Kong and mainland China.
Read More
Lung cancer illustration

Arrivent raises a $150M series A to in-license oncology assets

July 6, 2021
By Lee Landenberger
No Comments
Arrivent Biopharma Inc. has raised a series A financing worth up to $150 million to in-license compounds from China and bring them to the rest of the world. Arrivent’s focus is in oncology and its first in-licensed asset is furmonertinib, a third-generation EFGR tyrosine kinase inhibitor from Shanghai-based Allist Pharmaceuticals Co. Ltd.
Read More
DNA, dollars illustration

Sirnaomics closes $105M series E to advance polypeptide nanoparticle-based siRNA therapeutics in multiple cancers

July 6, 2021
By Elise Mak
No Comments
Just five days after raising $105 million in a series E financing round, RNA interference therapeutics specialist Sirnaomics Inc. obtained another IND approval from the FDA for its dual-targeting small interfering RNA (siRNA) inhibitor STP-707 to start a basket study in oncology. Sirnaomics’ CEO Patrick Lu told BioWorld in an exclusive interview that an I.V. administration of STP-707 will be tested to tackle solid cancers that may have metastasized into other potential areas or tissue types in the body.
Read More

Financings for July 6, 2021

July 6, 2021
No Comments
Biopharmas in Asia-Pacific raising money in public or private financings, including: Oncusp, Vaxthera.
Read More
Previous 1 2 … 8 9 10 11 12 13 14 15 16 … 35 36 Next

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Aug. 9, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Aug. 9, 2022.
  • Amvuttra

    Alnylam’s Amvuttra rare disease drug among positive recommendations from Europe’s CHMP

    BioWorld
    Alnylam Pharmaceuticals Inc.’s Amvuttra (vutrisiran), a treatment for the rare disease hereditary transthyretin-mediated amyloidosis, was among medicines...
  • Pig organ cells

    Whole body cellular function recovery in pigs after death

    Science
    A new system for restoring cell function and tissues in mammals after death could expand the availability of organs for transplantation. The research also opens...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing